首页/数据集/Bromodomain-containing protein BRPF1 as a therapeutic target for metastatic ovarian cancer

Bromodomain-containing protein BRPF1 as a therapeutic target for metastatic ovarian cancer

ChEBI2024-01-08 更新2026-07-12 收录

卵巢癌治疗

表观遗传药物靶点

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-13663 数据链接链接失效反馈

官方服务：

资源简介：

Bromodomain-containing protein BRPF1 as a therapeutic target for metastatic ovarian cancer

应用场景：

创建时间：

2024-01-08

相关数据集

Fig8

卵巢癌治疗

免疫细胞疗法

Schematic illustration of eNK-EXO enhance the anti-tumor effects against ovarian cancer by delivering chemotherapeutic drugs and reactivating NK cell functions

NIAID Data Ecosystem80

Crystal Structure of KDM4D with GF026 ligand

蛋白质复合物结构解析

表观遗传药物靶点

Crystal Structure of KDM4D with GF026 ligand Descriptor: 1,2-ETHANEDIOL, 2-[2-(methylsulfonylamino)ethylamino]pyridine-4-carboxylic acid, CHLORIDE ION, ... Authors: Malecki, P.H, Link, A, Weiss, M.S,

Protein Data Bank Japan2024-01-17 更新60

Table_1_A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.DOCX

卵巢癌治疗

剂量递增研究

Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-res

NIAID Data Ecosystem30

Inhibition of LSD1 enzymatic activity of SP-2577 and SP-2513 measured by Resorufin assay in a cell-free system.

LSD1酶活性抑制测定

表观遗传药物靶点

Inhibition of LSD1 enzymatic activity of SP-2577 and SP-2513 measured by Resorufin assay in a cell-free system.

NIAID Data Ecosystem80

ARID1A-mutated ovarian cancers depend on HDAC6 activity

卵巢癌治疗

表观遗传学

ARID1A, encoding a subunit of the SWI/SNF chromatin remodeling complex, is the most mutated epigenetic regulator in human cancers. ARID1A and TP53 mutations are typically mutually exclusive. Therap

NIAID Data Ecosystem40